To gain insight into the broader clinical implications of GFPT2 expression concerning the response to paclitaxel and survival rates in ovarian cancer patients, we reviewed data from individuals within TCGA database who underwent chemotherapy treatments containing paclitaxel. This evidence concerns the gene GFPT2 and ovarian carcinoma.